Stockscreener 앱 받기
0.9999
2.03%
0.0199
시간 외 거래:
1.00
0.000100
+0.01%
전일 마감가:
$0.98
열려 있는:
$0.97
하루 거래량:
59,963
Relative Volume:
0.41
시가총액:
$59.67M
수익:
-
순이익/손실:
$-112.67M
주가수익비율:
-0.4739
EPS:
-2.11
순현금흐름:
$-79.26M
1주 성능:
-0.01%
1개월 성능:
-4.77%
6개월 성능:
-23.08%
1년 성능:
-23.08%
1일 변동 폭
$0.9547
$1.01
1주일 범위
$0.9301
$1.03
52주 변동 폭
$0.69
$1.60
크로노스 Stock (KRON) Company Profile
명칭
Kronos Bio Inc
전화
(650) 781-5200
주소
1300 S. EL CAMINO REAL, SAN MATEO
크로노스 Stock (KRON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-09-14 | 개시 | Berenberg | Buy |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-06-24 | 개시 | H.C. Wainwright | Buy |
| 2020-11-03 | 개시 | Cowen | Outperform |
| 2020-11-03 | 개시 | Goldman | Buy |
| 2020-11-03 | 개시 | Jefferies | Buy |
| 2020-11-03 | 개시 | Piper Sandler | Overweight |
모두보기
크로노스 주식(KRON)의 최신 뉴스
Kronos Bio, Inc. (NASDAQ:KRON) Position Increased by Forefront Analytics LLC - Defense World
Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - StockTitan
Kronos Bio to Present Data at ACR Convergence 2024 to - GlobeNewswire
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World
Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World
Integral Health Asset Management LLC Acquires 45,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
How the (KROS) price action is used to our Advantage - Stock Traders Daily
How does Keros Therapeutics Inc (KROS) change from a tortoise to a hare? - SETE News
Kronos Bio highlights istisociclib data at Ovarian Cancer Research Symposium - TipRanks
71,428 Shares in Korro Bio, Inc. (NASDAQ:KRRO) Acquired by Tri Locum Partners LP - MarketBeat
Kronos Bio Highlights Data at AACR Ovarian Cancer Research - GlobeNewswire
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer - StockTitan
Keros Therapeutics (NASDAQ:KROS) Receives New Coverage from Analysts at Guggenheim - MarketBeat
Guggenheim starts Keros Therapeutics with 'buy' on lung disorder drug potential - XM
Guggenheim bullish on Keros Therapeutics stock driven by PAH treatment prospects - Investing.com Australia
Gogo Inc. (NASDAQ:GOGO) Shares Sold by Yarra Square Partners LP - Defense World
American Century Companies Inc. Has $13.63 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World
Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Rhumbline Advisers - Defense World
Pharmacosmos after major acquisition: “The next six months are about integrating G1 well” - MedWatch
Understanding CRON stock ratios for better investment decisions - US Post News
DekaBank Deutsche Girozentrale Has $4.25 Million Holdings in Dollar Tree, Inc. (NASDAQ:DLTR) - Defense World
Kronos Bio, Inc. (NASDAQ:KRON) Short Interest Update - MarketBeat
ABIVAX Société Anonyme (NASDAQ:ABVX) Sees Large Growth in Short Interest - Defense World
After Plunging -5.53% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - Yahoo Finance
Kronos Bio Announces Participation in Medical and Investor Conferences in September - Marketscreener.com
Kronos Bio Announces Participation in Medical and Investor Conferences in September - GlobeNewswire
Kronos Bio Announces Participation in Medical and Investor Conferences in September - Yahoo Finance
The Psychology of Kronos Bio Inc Inc. (KRON) Price Performance: Understanding Market Sentiment - The InvestChronicle
Kronos Bio Inc (KRON) rating initates by Berenberg - Knox Daily
HC Wainwright Equities Analysts Boost Earnings Estimates for Kronos Bio, Inc. (NASDAQ:KRON) - MarketBeat
Kronos Bio (NASDAQ:KRON) Given "Buy" Rating at HC Wainwright - MarketBeat
Kronos Bio (NASDAQ:KRON) Earns Buy Rating from HC Wainwright - Defense World
KRON (Kronos Bio) Cash From Other Investing Activities : $0.00 Mil (TTM As of Jun. 2024) - GuruFocus.com
Analyzing Kronos Bio Inc (KRON) After Recent Trading Activity - Knox Daily
Kronos Bio Second Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
KRON Stock Earnings: Kronos Bio Beats EPS, Beats Revenue for Q2 2024 - InvestorPlace
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates - Zacks Investment Research
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update - GlobeNewswire
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update - StockTitan
Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline Update - Yahoo Finance
Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Kronos Bio, Inc. (KRON) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
HC Wainwright Comments on Kronos Bio, Inc.'s Q2 2024 Earnings (NASDAQ:KRON) - MarketBeat
Kronos Bio (NASDAQ:KRON) Rating Reiterated by HC Wainwright - American Banking and Market News
Q2 2024 EPS Estimates for Kronos Bio, Inc. (NASDAQ:KRON) Boosted by HC Wainwright - Defense World
Jacobs Levy Equity Management Inc. Has $77,000 Holdings in Kronos Bio, Inc. (NASDAQ:KRON) - Defense World
Kronos Bio, Inc. (NASDAQ:KRON) Expected to Post FY2025 Earnings of ($1.44) Per Share - Defense World
Benessere Capital Acquisition (OTCMKTS:BENEU) Shares Down 0% - Defense World
HC Wainwright Reiterates Buy Rating for Kronos Bio (NASDAQ:KRON) - Defense World
Kronos Bio, Inc. Forecasted to Post FY2025 Earnings of ($1.44) Per Share (NASDAQ:KRON) - MarketBeat
크로노스 (KRON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):